refaat abusamra

Careful patient selection for partial prostatectomy is judged by outcomes and @drjkaouk is here to show us it is possible and safe @CleClinicUroRes no tomatoes 🍅 here just safe surgery after multi D discussion @OhioUroSociety

Get updated @EUplatinum published results in interactive format on our WhatsApp channel whatsapp.com/channel/0029Vb… such as 👇👇 from updated pure 01 5 year data europeanurology.com/article/S0302-…

🎙️ Active surveillance in prostate cancer: where are we in 2026? UROONCO PCa Associate Editor @dr_rajwa speaks with @roodvdb and @JGomezRivas about the evolving role of active surveillance in prostate cancer care. This discussion explores: 🔹 Optimal patient selection 🔹 The role of MRI and PSA in monitoring 🔹 Risk stratification strategies 🔹 Follow-up protocols and transitions to watchful waiting 🔹 Emerging tools such as AI and genomics The conversation highlights how personalized care, quality of life, and reducing overtreatment remain central—while maintaining strong oncological outcomes. 📺 Watch the interview and stay updated on the future of patient-centered prostate cancer management. @Uroweb @EAU_Uroonco #ProstateCancer #ActiveSurveillance #UroOncology #EAU26 #Urology prostate.uroonco.uroweb.org/video/active-s…

The April issue of European Urology is now online! 📢 Explore the latest research, insights, and expert perspectives 🔬 Read now on our website 👇 europeanurology.com/current #EuropeanUrology #Urology #Research #MedTwitter #AcademicTwitter

This paper relates membranous urethral length to postoperative stress urinary incontinence after HoLEP... It kind of blames the patient's anatomy for the occurrence of postoperative stress incontinence. I think with these incidences of post-op incontinence, the surgical technique used by the authors is a huge problem. Or is it that I only operate on patients with long urethral lengths to get way much lower rates of incontinence? (49,7% SUI at 1 month shows a flaw with surgical technique)

Stage-based treatment for nonmuscle invasive #BladderCancer. #NMIBC is entering a new era, with novel therapies achieving one-year response rates around 50–60% in BCG-unresponsive disease and ablative options like UGN-102 reducing repeat TURBT in intermediate-risk patients. Dr. Ricardo Rendon @DalhousieU joins @zklaassen_md @GACancerCenter underscoring that these advances heighten the need for adherence to risk-based guidelines, centralized care for complex cases, and ongoing education and trial participation to manage increasingly personalized treatment strategies. #WatchNow > bit.ly/4kpcnnd

Management of post-micturition dribble in men. @AhmedAlbakr @CleClinicUro joins Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro to discuss this systematic review, summarizing 4 trials showing that tadalafil and udenafil significantly improve Hallym PMD scores and leakage volumes, while pelvic floor exercises provide durable benefit and urethral milking offers quicker, less sustained relief—highlighting that PMD is measurable and treatable with both behavioral and pharmacologic strategies. #WatchNow on UroToday > bit.ly/40iAzy9 @icsoffice

After our session at #EAU26 I met with Jeremy Bellaiche from shuf.ai to integrate the main messages on physical exercise and cognitive performance in a short #podcast. Very nice experience to start with and hope to work together on more topics in the future! Great tool for MDs to generate informative and individualized podcasts @jeremy02766919 shuf.ai #PhysicalExercise #CognitiveFunction #Exercisumab #BrainFertilizer @uroweb 👉shuf.ai/episode-player…

Clinical and molecular criteria for aggressive variant #ProstateCancer. @aaparicioMD @MDAndersonNews joins Oliver Sartor, MD @EJHospital to discuss how AVPC captures androgen‑indifferent tumors with combined tumor suppressor defects, early data from chemo + anti–PD‑1 followed by PARP inhibitor maintenance showing benefit in a subset, and the urgent need for better predictive biomarkers. Dr. Aparicio calls for platform trials to test rational combinations and match therapies to specific biological subsets in this hard‑to‑treat disease. #WatchNow > bit.ly/3O9Hze8 @myESMO

Excellent summary on #NMIBC and #UTUC treatment, diagnostics and biomarkers from #EAU26 by Joost Boormans 👉urosource.uroweb.org/resource-centr… Key takeaways on #NMIBC and #utDNA/urine biomarkers 👇 ☑️#Erdafitinib-iDRS shows strong activity as ablative treatment in FGFR-altered IR-NMIBC → 6-month CR rate: 89% + as adjuvant treatment in BCG-treated HR-NMIBC, adjuvant erdafitinib shows → 1-year RFS: 83% ☑️#utDNA highly prognostic → patients #MRD-negative at baseline and week 12 had ~100% 1-yr RFS #THOR2 ☑️For HR-NMIBC, strategies that may shape future care are optimized intravesical therapy (e.g. BCG + MMC) + biomarker-guided surveillance ➡️opens promising perspectives for biomarker-guided follow-up and treatment decisions #NMIBC #BladderCancer #UroOnc @oncodaily @Uroweb @urotoday

Nectin-4 is expressed in almost all urothelial cancers . Nectin-4 fluorescence imaging during cystoscopy makes sense and seems to work well (see below) #EAU26 @urotoday . This potentially improves diagnostic accuracy. It would be good to generate large randomized data. @OncoAlert

New oncology data should answer 4 simple questions: 1. Who benefits? 2. How much? 3. At what cost? 4. And for which real patient in front of us? #cancer

PRostate cancer guidelines 2026 update. Digital rectal exam NOW no more recommended for Asymptomatic men SO NO MORE FOR Screening Important for standing and for early diagnosis for SYMPTOMS only @Uroweb

Urinary markers versus cystoscopy: Is it time to ditch the scope? Presentation by Paolo Gontero, MD, @jteoh_hk, and @LAUrology_NL. #EAU26 written coverage by @RKSayyid > bit.ly/4b8zb7I @Uroweb

@brookmans76 @EUplatinum @Uroweb Congratulations 🎊

Great to be @EUplatinum Platinum Circle Reviewer 🥂@Uroweb #EAU26

#EAU26 ctDNA after cystectomy is promising… but not ready for prime time Dr. Masson-Lecomte highlights key hurdles: 🔹 Complex & costly infrastructure 🔹 One post-RC test is not enough 🔹 Rapidly evolving systemic therapy landscape 🔹 ctDNA ≠ local disease biology @uroweb @UroToday

Does bladder-sparing = better pt outcomes in recurrent HG NMIBC? CISTO shows better global health, emotional & mental functioning after RC The hidden costs of BST ‼️⬆️ recurrence ‼️ongoing surveillance burden ‼️worse emotional function Shared decision making essential #EAU26

Discussion #EAU26 about the future of cystectomy neoadjuvant treatment and radiotherapy in muscle invasive bladder cancer. Things are changing rapidly. With pCR rates >50% for EVP many patients will want to keep their bladders. An era of ‘EVP 1st and ask questions later’ maybe a reality soon. Generation of EVP bladder sparing data is a priority. @Uroweb @EUplatinum

🇬🇧☎️🫖London calling! CUA is present in London, do not miss the CUA-EAU Joint Session! And come visit us at the CUA booth BL15! eaucongress.uroweb.org/scientific-pro…

For years I told patients and relatives: 'Screening saves lives, don't wait.' And I lay on that table, heart racing. A polyp was found and removed instantly. Early detection isn't just data, it's a gift of life. Don't delay. For yourself! #coloncancer #PreventiveCare @drkeithsiau @KimmieNgMD @ASCO @myESMO @DrCatharineY @jamecancerdoc